TOPLINE:
More than half (56.2%) of patients who are newly diagnosed with lymphoma and myeloma experience clinically significant anxiety or depression symptoms, with lower financial satisfaction and medical mistrust increasing anxiety risk. Depression symptoms, present in 27.5% of patients, were linked to significantly lower quality-of-life (QOL) scores.
METHODOLOGY:
- A cross-sectional survey study conducted at Dana-Farber Cancer Institute in Boston included 200 adult patients (response rate 74.9%) within 6 months of initial lymphoma or myeloma diagnosis between July 2021 and September 2022.
- Researchers used the Hospital Anxiety and Depression Scale to assess anxiety and depression symptoms, with scores > 8 indicating clinically significant symptoms.
- Analysis examined sociodemographic factors associated with…